版本:
中国

BRIEF-AstraZeneca says U.S. FDA accepts new drug application for Lynparza

March 28 AstraZeneca Plc

* U.S. FDA has accepted company's new drug application (NDA) for Lynparza (olaparib) tablets

* Granted priority review status with a prescription drug user fee act (PDUFA) set for Q3 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐